Author(s): Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW,
Abstract Share this page
Abstract Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations. Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
This article was published in Leuk Res
and referenced in Journal of Leukemia